Literature DB >> 12388707

Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice.

Shivaprakash Gangappa1, Sharookh B Kapadia, Samuel H Speck, Herbert W Virgin.   

Abstract

While antiviral antibody plays a key role in resistance to acute viral infection, the contribution of antibody to the control of latent virus infection is less well understood. Gammaherpesvirus 68 (gammaHV68) infection of mice provides a model well suited to defining contributions of specific immune system components to the control of viral latency. B cells play a critical role in regulating gammaHV68 latency, but the mechanism(s) by which B cells regulate latency is not known. In the experiments reported here, we determined the effect of passively transferred antibody on established gammaHV68 latency in B-cell-deficient (B-cell(-/-)) mice. Immune antibody decreased the frequency of cells reactivating ex vivo from latency in splenocytes (>10-fold) and peritoneal cells (>100-fold) and the frequency of cells carrying latent viral genome in splenocytes (>5-fold) and peritoneal cells (>50-fold). This effect required virus-specific antibody and was observed when total and virus-specific serum antibody concentrations in recipient B-cell(-/-) mice were <8% of those in normal mice during latent infection. Passive transfer of antibody specific for the lytic cycle gammaHV68 RCA protein, but not passive transfer of antibody specific for the v-cyclin protein or the latent protein M2, decreased both the frequency of cells reactivating ex vivo from latency and the frequency of cells carrying the latent viral genome. Therefore, antibody specific for lytic cycle viral antigens can play an important role in the control of gammaherpesvirus latency in immunocompromised hosts. Based on these findings, we propose a model in which ongoing productive replication is essential for maintaining high levels of latently infected cells in immunocompromised hosts. We confirmed this model by the treatment of latently infected B-cell(-/-) mice with the antiviral drug cidofovir.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388707      PMCID: PMC136779          DOI: 10.1128/jvi.76.22.11460-11468.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.

Authors:  C A Janeway; J Ron; M E Katz
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

2.  T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.

Authors:  Y Ron; J Sprent
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

3.  Requirement for CD40 ligand, CD4(+) T cells, and B cells in an infectious mononucleosis-like syndrome.

Authors:  J W Brooks; A M Hamilton-Easton; J P Christensen; R D Cardin; C L Hardy; P C Doherty
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

4.  Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus.

Authors:  Scott A Tibbetts; Linda F van Dyk; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  Virological and pathological features of mice infected with murine gamma-herpesvirus 68.

Authors:  N P Sunil-Chandra; S Efstathiou; J Arno; A A Nash
Journal:  J Gen Virol       Date:  1992-09       Impact factor: 3.891

6.  Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo.

Authors:  N P Sunil-Chandra; S Efstathiou; A A Nash
Journal:  J Gen Virol       Date:  1992-12       Impact factor: 3.891

7.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.

Authors:  S N Isaacs; G J Kotwal; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

8.  Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection.

Authors:  Sharookh B Kapadia; Beth Levine; Samuel H Speck; Herbert W Virgin
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

9.  Identification of the in vivo role of a viral bcl-2.

Authors:  Shivaprakash Gangappa; Linda F van Dyk; Travis J Jewett; Samuel H Speck; Herbert W Virgin
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity.

Authors:  T A McNearney; C Odell; V M Holers; P G Spear; J P Atkinson
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  43 in total

1.  Effective vaccination against long-term gammaherpesvirus latency.

Authors:  Scott A Tibbetts; J Scott McClellan; Shivaprakash Gangappa; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Maintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes.

Authors:  Linda F van Dyk; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.

Authors:  James Scott McClellan; Scott A Tibbetts; Shivaprakash Gangappa; Kelly A Brett; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection.

Authors:  Rebecca L Sparks-Thissen; Douglas C Braaten; Scott Kreher; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Early establishment of gamma-herpesvirus latency: implications for immune control.

Authors:  Emilio Flaño; Qingmei Jia; John Moore; David L Woodland; Ren Sun; Marcia A Blackman
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

Review 6.  Immune regulation of viral infection and vice versa.

Authors:  Herbert W Virgin
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  A gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge.

Authors:  Janice M Moser; Michael L Farrell; Laurie T Krug; Jason W Upton; Samuel H Speck
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Memory generation and maintenance of CD8+ T cell function during viral persistence.

Authors:  Stephanie S Cush; Kathleen M Anderson; David H Ravneberg; Janet L Weslow-Schmidt; Emilio Flaño
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

9.  The M10 locus of murine gammaherpesvirus 68 contributes to both the lytic and the latent phases of infection.

Authors:  B Flach; B Steer; N N Thakur; J Haas; H Adler
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  NF-kappaB p50 plays distinct roles in the establishment and control of murine gammaherpesvirus 68 latency.

Authors:  Laurie T Krug; Christopher M Collins; Lisa M Gargano; Samuel H Speck
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.